NZ533987A - Uses of mammalian cytokine; agonists and antagonists for modulating antigen presenting cell priming of T cells - Google Patents

Uses of mammalian cytokine; agonists and antagonists for modulating antigen presenting cell priming of T cells

Info

Publication number
NZ533987A
NZ533987A NZ533987A NZ53398703A NZ533987A NZ 533987 A NZ533987 A NZ 533987A NZ 533987 A NZ533987 A NZ 533987A NZ 53398703 A NZ53398703 A NZ 53398703A NZ 533987 A NZ533987 A NZ 533987A
Authority
NZ
New Zealand
Prior art keywords
leu
ser
val
thr
glu
Prior art date
Application number
NZ533987A
Other languages
English (en)
Inventor
Waal Malefyt Rene De
Yong-Jun Liu
Marehalli L Nagalakshmi
Vassili Soumelis
Norhiko Watanabe
Wei Yuan
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27734298&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ533987(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of NZ533987A publication Critical patent/NZ533987A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/19Dendritic cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/20Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24Antigen-presenting cells [APC]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41Vertebrate antigens
    • A61K40/42Cancer antigens
    • A61K40/4231Cytokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5418IL-7
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/50Cellular immunotherapy characterised by the use of allogeneic cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NZ533987A 2002-02-01 2003-01-30 Uses of mammalian cytokine; agonists and antagonists for modulating antigen presenting cell priming of T cells NZ533987A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35350902P 2002-02-01 2002-02-01
PCT/US2003/002758 WO2003065985A2 (en) 2002-02-01 2003-01-30 Uses of mammalian cytokine; related reagents

Publications (1)

Publication Number Publication Date
NZ533987A true NZ533987A (en) 2007-04-27

Family

ID=27734298

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ533987A NZ533987A (en) 2002-02-01 2003-01-30 Uses of mammalian cytokine; agonists and antagonists for modulating antigen presenting cell priming of T cells

Country Status (11)

Country Link
US (5) US20030186875A1 (enExample)
EP (3) EP1487865A4 (enExample)
JP (4) JP2005516606A (enExample)
AU (1) AU2003208888B2 (enExample)
CA (1) CA2474011C (enExample)
DK (1) DK2311869T3 (enExample)
ES (1) ES2399503T5 (enExample)
MX (1) MXPA04007426A (enExample)
NZ (1) NZ533987A (enExample)
PT (1) PT2311869E (enExample)
WO (1) WO2003065985A2 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861227B2 (en) * 1998-03-19 2005-03-01 Human Genome Sciences, Inc. Antibodies to cytokine receptor common gamma chain like
ATE362534T2 (de) 1998-11-13 2007-06-15 Immunex Corp Menschliche tslp nukleinsäuren und polypeptide
US6890734B2 (en) * 2000-11-10 2005-05-10 Schering Corporation Nucleic acids encoding a cytokine receptor complex
PL371773A1 (en) * 2001-07-23 2005-06-27 Immunex Corporation Modified human thymic stromal lymphopoietin
ES2399503T5 (es) * 2002-02-01 2021-04-08 Merck Sharp & Dohme Uso de reactivos relacionados con citocinas de mamíferos
DK1651247T3 (da) * 2003-07-18 2009-01-12 Schering Corp Behandling og diagnose af neoplasmer ved anvendelse af Thymic Stromal Lymphopoietin
TR201901268T4 (tr) * 2004-03-22 2019-02-21 Mesoblast Int Sarl Mezenkimal kök hücreleri ve bunların kullanımları.
US20050249712A1 (en) * 2004-03-23 2005-11-10 The Government Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Methods for use of TSLP and agonists and antagonists thereof
US20060171943A1 (en) * 2005-02-01 2006-08-03 Amgen Inc. Compositions and methods of treating fibrotic disorders
US8871715B2 (en) 2005-10-14 2014-10-28 Alltech, Inc. Use of selenium compounds, especially selenium yeasts for altering cognitive function
GB0603683D0 (en) * 2006-02-23 2006-04-05 Novartis Ag Organic compounds
AU2007334499B2 (en) * 2006-12-14 2014-04-24 Merck Sharp & Dohme Corp. Engineered anti-TSLP antibody
KR20100034015A (ko) * 2007-06-20 2010-03-31 아이알엠 엘엘씨 알레르기 질환 치료를 위한 방법 및 조성물
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US20120124701A1 (en) 2008-02-01 2012-05-17 Ceres, Inc. Promoter, promoter control elements, and combinations, and use thereof
US12331304B2 (en) 2008-02-01 2025-06-17 Ceres, Inc. Promoter, promoter control elements, and combinations, and uses thereof
EP2213682A1 (en) 2009-01-30 2010-08-04 Institut Curie TSLP promotes immune evasion and persistence of viruses
AU2010315304B2 (en) 2009-11-04 2014-03-27 Merck Sharp & Dohme Llc Engineered anti-TSLP antibody
JPWO2012001889A1 (ja) * 2010-06-28 2013-08-22 国立大学法人東北大学 Tslpを恒常的に高発現する細胞、及び前記細胞を利用したtslp調節剤のスクリーニング方法
WO2012007495A1 (en) 2010-07-15 2012-01-19 F. Hoffmann-La Roche Ag Antibodies specifically binding to human tslpr and methods of use
JP2012032655A (ja) * 2010-07-30 2012-02-16 Fujimori Sangyo Kk ホログラム付きラミネートフィルム及びその製造方法、これを用いた容器
US20150104465A1 (en) * 2011-10-28 2015-04-16 Merck Sharp & Dohme Corp. Il-19 as a biomarker of tslp treatment
WO2013067051A1 (en) 2011-11-03 2013-05-10 Merck Sharp & Dohme Corp. Biomarkers for tslp treatment
EA038332B1 (ru) 2015-09-09 2021-08-10 Новартис Аг Молекулы, связывающиеся с тимусным стромальным лимфопоэтином (tslp), и способы применения таких молекул
CU24533B1 (es) 2015-09-09 2021-07-02 Novartis Ag Anticuerpos o fragmentos de los mismos que se unen a linfopoyetina estromal tímica (tslp) y composiciones farmacéuticas de los mismos

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4732863A (en) 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US6982320B2 (en) * 1998-03-19 2006-01-03 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US6844170B1 (en) * 1998-03-19 2005-01-18 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US6861227B2 (en) * 1998-03-19 2005-03-01 Human Genome Sciences, Inc. Antibodies to cytokine receptor common gamma chain like
JP2002526079A (ja) * 1998-09-21 2002-08-20 シェーリング コーポレイション ヒトインターロイキン−b50、治療的使用
US20030099947A1 (en) * 1998-09-21 2003-05-29 Bazan J. Fernando Mammalian cytokines; related reagents and methods
ATE362534T2 (de) * 1998-11-13 2007-06-15 Immunex Corp Menschliche tslp nukleinsäuren und polypeptide
WO2001095710A1 (en) * 2000-06-16 2001-12-20 Nakanishi, Kenji Caspase 1 gene transfer animal
PT1297017E (pt) * 2000-06-19 2012-09-04 Gen Hospital Corp Composições e métodos de anticorpos monoclonais e policlonais específicos para subpopulações de célula t
AU2001271624A1 (en) * 2000-06-28 2002-01-08 Whitehead Institute For Biomedical Research Thymic stromal lymphopoietin receptor molecules and uses thereof
US6890734B2 (en) * 2000-11-10 2005-05-10 Schering Corporation Nucleic acids encoding a cytokine receptor complex
ES2399503T5 (es) * 2002-02-01 2021-04-08 Merck Sharp & Dohme Uso de reactivos relacionados con citocinas de mamíferos

Also Published As

Publication number Publication date
EP1487865A2 (en) 2004-12-22
AU2003208888B2 (en) 2006-10-19
US20030186875A1 (en) 2003-10-02
EP2311869B2 (en) 2020-06-17
EP2311869A1 (en) 2011-04-20
US20070020262A1 (en) 2007-01-25
WO2003065985A3 (en) 2004-10-14
CA2474011A1 (en) 2003-08-14
ES2399503T3 (es) 2013-04-01
ES2399503T5 (es) 2021-04-08
JP5519946B2 (ja) 2014-06-11
EP1487865A4 (en) 2005-12-14
JP2012184259A (ja) 2012-09-27
AU2003208888A1 (en) 2003-09-02
JP2014156478A (ja) 2014-08-28
US20090017018A1 (en) 2009-01-15
EP2311869B1 (en) 2012-12-19
JP2005516606A (ja) 2005-06-09
JP2009132730A (ja) 2009-06-18
CA2474011C (en) 2014-03-25
MXPA04007426A (es) 2004-10-11
US20110229434A1 (en) 2011-09-22
EP2077277A1 (en) 2009-07-08
US20100136003A1 (en) 2010-06-03
PT2311869E (pt) 2013-03-04
DK2311869T3 (da) 2013-03-18
WO2003065985A2 (en) 2003-08-14

Similar Documents

Publication Publication Date Title
US20090017018A1 (en) Uses of mammalian cytokine: related reagents
Takatsu Interleukin-5 and IL-5 receptor in health and diseases
KR100895749B1 (ko) Nkg2d의 조절
US20060039910A1 (en) Methods and compositions for treating allergic inflammation
JP2003524644A (ja) Cd40−結合性apc−活性化分子
JP2017048235A (ja) 細胞傷害活性抗lag−3モノクローナル抗体および臓器移植拒絶および自己免疫疾患の治療または予防における該抗体の使用方法
JP2007238630A (ja) 抗−T−BAM(CD40−L)モノクローナル抗体5c8の治療適用
JP2009543579A (ja) 抗炎症反応のための標的としてのWSX−1/p28
EP2292760A2 (en) Mammalian cytokines, receptors, related reagents and methods
Little et al. Interleukin-16 and peptide derivatives as immunomodulatory therapy in allergic lung disease
US8246959B1 (en) Dendritic cell-associated lectin-like molecules, compositions and methods of use
CA2231433A1 (en) Method for modulating cell apoptosis
Deng The contribution of IL-17A and IL-17F in the pathogenesis of antibody-induced Epidermolysis Bullosa Acquisita
WO2003086457A2 (en) Method of treating or preventing autoimmune disease

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 30 JAN 2016 BY THOMSON REUTERS

Effective date: 20130305

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JAN 2017 BY THOMSON REUTERS

Effective date: 20151213

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JAN 2018 BY THOMSON REUTERS

Effective date: 20161214

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JAN 2019 BY THOMSON REUTERS

Effective date: 20171214

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JAN 2020 BY THOMSON REUTERS

Effective date: 20181220

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JAN 2021 BY THOMSON REUTERS

Effective date: 20191217

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JAN 2022 BY THOMSON REUTERS

Effective date: 20201215

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JAN 2023 BY THOMSON REUTERS

Effective date: 20211207

ASS Change of ownership

Owner name: MERCK SHARP + DOHME LLC, US

Effective date: 20220922

EXPY Patent expired